Excelsior Biopharma Inc. (TPEX:6496)

Market Cap	1.27B -17.2%
Revenue (ttm)	898.26M +4.2%
Net Income	-183.17M
EPS	-3.97
Shares Out	46.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,063
Average Volume	11,727
Open	26.40
Previous Close	27.40
Day's Range	26.40 - 27.15
52-Week Range	21.55 - 30.55
Beta	-0.06
RSI	51.63
Earnings Date	May 8, 2026

About Excelsior Biopharma

Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specialty medicine and public health products. In addition, it is involved in importing and exporting of active pharmaceutical ingredients, food, and cosmece...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1986
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6496

Financial Performance

In 2025, Excelsior Biopharma's revenue was 898.26 million, an increase of 4.22% compared to the previous year's 861.91 million. Losses were -183.17 million, 85.6% more than in 2024.